This dramatically reduces the risk of relapse in breast-cancer patients whose tumours make a protein called Her2/neu, and only those women whose tumours produce this protein will respond to the drug.

• 它能大大降低体内肿瘤可以产生Her2/neu蛋白的乳腺癌患者复发的风险，并且，只有那些体内肿瘤可以产生这种蛋白的女性会对该药物做出反应。